The Chemours Company CC recently announced the launch of a full-scale product trial with NTT DATA and a leading regional ...

Chemours, a global leader in delivering innovative performance chemistry, today announced the launch of a full-scale product trial with NTT DATA and a leading regional engineering firm, Hibiya ...

Chemours Co. plans to add the chief executive officer of Vision One Management Partners to its board as it seeks to avoid a ...

Chemours ( NYSE: CC) is preparing to appoint the chief executive of Vision One Management Partners to its board in an effort ...

Company announced the launch of a full-scale product trial with NTT Data and a regional engineering firm, Hibiya Engineering, ...

Chemours joins forces with NTT DATA and Hibiya Engineering, Ltd. to advance data center two-phase immersion cooling with ...

North Carolina ordered Chemours to expand PFAS well testing, adding 150,000 homes in six counties, including Harnett and Hoke ...

Chemours is expanding sampling eligibility to additional homes inside and neighboring southeastern North Carolina at the ...

It is unclear what actions the Trump administration will take, if any, to protect the public against PFAS, linked to cancer and other health problems.

The Chemours Company (NYSE:CC) shareholders might understandably be very concerned that the share price has dropped 33% in the last quarter. On the bright side the share price is up over the last half ...

The N.C. Department of Environmental Quality is continuing Chemours’ search for groundwater contamination beyond the Lower ...

Barclays analyst Michael Leithead maintained a Hold rating on Chemours Company (CC – Research Report) today and set a price target of $19.00.